What does the evidence say about Omega-3 Dry Eye Randomized Trial?

The current Migaku evidence database contains 4 reusable source documents for Omega-3 Dry Eye Randomized Trial. This answer focuses on benefits, uncertainty, and practical interpretation. - Between-group comparisons revealed significantly higher improvements in the BLT group: Schirmer's test (Schirmer I) improved by MD = 8.7 (95% CI: 7.64-9.76; p = 0.001), TBUT by MD = 2.97 (95% CI: 1.7-4.3; p = 0.007), and DEQS decreased by MD = - 24.1 (95% CI: -37 to - 17.1; p = 0.002). [Mohamed Elsayed Saad E (2026); evidence level 2] - To examine the short-term therapeutic effects of Bioptron light therapy (BLT) on dry eye disease (DED) in postmenopausal women. [Mohamed Elsayed Saad E (2026); evidence level 2] - Sixty postmenopausal women diagnosed with DED, aged 50-62 years with a body mass index ≤ 30 kg/m², were randomly assigned to two equal groups. [Mohamed Elsayed Saad E (2026); evidence level 2] - Purpose To evaluate whether omega-3 fatty acid supplementation is linked to a reduced glaucoma risk in individuals with dry eye disease. [Pan SY (2026); evidence level 3] - The lower risks of ocular hypertension and POAG associated with omega-3 use remained consistent across those aged 60 years or older, females, Whites, and other demographic categories. [Pan SY (2026); evidence level 3] Evidence levels are sorting aids, not final clinical grades. Level 1 usually indicates systematic-review style evidence, level 2 indicates randomized trials or public-health guidance, and lower levels need more cautious wording. This page is educational. People with medical conditions, pregnancy, medication use, or unusual symptoms should ask a qualified clinician before changing supplements, medication, or treatment routines.